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Advanced glycation end products (AGE) are central to the development of
cardiovascular complications associated with diabetes mellitus. AGE may
alter cellular function through cross-linking of cellular proteins or by activat-
ing the AGE receptor (RAGE). However, the signalling molecules involved
during AGE stimulation in cardiomyocytes remain unclear. Here, we investi-
gated the effects of AGE treatment on intracellular calcium homeostasis of
isolated cardiomyocytes and studied the activation of signalling molecules
involved in this process. Treatment of cardiomyocytes with AGE for 24 h
resulted in a dose-dependent reduction in calcium transient amplitude, reach-
ing a maximum 50% reduction at a dose of 1 mgmL1. This was accompa-
nied with a 32% reduction in sarcoplasmic reticulum calcium content but
without any detectable changes in the expression of major calcium channels.
Mechanistically, we observed a significant increase in the production of reac-
tive oxygen species (ROS) in AGE-treated cardiomyocytes and enhancement
of NADPH oxidase activity. This was accompanied with activation of p38
kinase and nuclear translocation of NF-jB, and subsequently induction of
inducible NO synthase (iNOS) expression, leading to excessive nitric oxide
production. Overall, our data reveal the molecular signalling that may under-
lie the alteration of intracellular calcium homeostasis in cardiac myocytes due
to AGE stimulation. This may provide new insights into the pathophysiologi-
cal mechanisms of the development of diabetic cardiomyopathy.
The prevalence of diabetes is increasing with the pro-
jected prevalence of diabetes worldwide and is escalat-
ing from 285 million in 2010 to 439 million in 2030
[1]. Cardiovascular complications are the principle
causes of morbidity and mortality in patients with dia-
betes, accounting for up to 68% of diabetic fatalities [2].
These include atherosclerosis, coronary heart disease,
congestive heart failure and diabetic cardiomyopathy.
The latter refers to a condition where diabetic condi-
tion alters cardiac structure and function directly with-
out affecting the vasculature and independent of the
occurrence of hypertension or valvular disease [3].
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Diabetic cardiomyopathy has been associated with
both type 1 and type 2 diabetes and is characterized by
early-onset diastolic dysfunction followed by systolic
dysfunction [4]. It is believed that both structural and
functional changes play significant roles in the process.
For example, the extent of cardiac fibrosis is much
greater in both animal models and human patients with
diabetic cardiomyopathy [5]. Furthermore, diabetes may
also impair cardiomyocyte excitation–contraction cou-
pling and hence alter intracellular calcium homeostasis
[6,7], possibly explaining the reduction in cardiac con-
tractile function in diabetic cardiomyopathy.
However, the mechanism of how prolonged hyper-
glycaemia can cause cardiomyopathy is not completely
understood. One of the possible factors that may be
involved is the production and accumulation of
advanced glycation end products (AGEs) [8]. AGEs are
heterogenous group of molecules resulting from the
nonenzymatic glycation and oxidation of proteins and
lipids in the presence of reducing sugars [9]. Accumulat-
ing evidence showed crucial contribution of AGEs in
the evolution and progression of heart failure in patients
with diabetes as clinical studies have found correlation
between serum AGE levels with severity of heart failure
and coronary heart disease [10,11] as well as with sys-
tolic and diastolic cardiac dysfunction [12,13].
It is understood that the cardiac effects of AGEs
may be through cross-linking of extracellular matrix
and/or activation of the AGE receptor (RAGE) (re-
viewed in [14]). AGEs may cross-link with extracellular
matrix proteins such as collagen, laminin, and elastin
leading to the impaired degradation and increased
stiffness [15]. On the other hand, AGE may affect
intracellular signalling pathways via activation of
RAGE. RAGE signalling has been widely investigated
in vascular endothelial and smooth muscle cells as well
as in macrophages [16]; however, its role in the car-
diomyocytes is not completely understood. Here, we
investigated the direct effects of AGE stimulation on
cardiomyocytes focusing on examining the effects of
AGE stimulation on the intracellular calcium dynam-
ics as well as investigating the signalling molecules that
may be affected by AGE stimulation.
Materials and methods
Isolation and culture of rat primary neonatal
cardiomyocytes
Neonatal rat cardiomyocytes were isolated from two- to
three-day-old of Sprague Dawley rat neonates using the
protocol described previously [17,18]. All experiments
involving animals were performed in accordance with the
United Kingdom Animals (Scientific Procedures) Act 1986
and were approved by the University of Manchester Ethics
Committee. For NRCMs isolation, extracted neonatal
hearts were preserved into ice-cold filter-sterilized ADS
solution (116 mM NaCl, 20 mM HEPES, 1 mM NaH2PO4,
5.5 mM glucose, 5.5 mM KCl, 1 mM MgSO4, pH 7.35
adjusted with NaOH). The top section of the heart was
excised to remove the atria. Then, the remaining part of
the hearts were cut into half and were incubated in ADS
solution containing 0.6 mgmL1 collagenase A (Roche
Applied Bioscience, Mannheim, Germany) and
0.6 mgmL1 pancreatin (Sigma-Aldrich, St. Louis, MO,
USA) at 37 °C for 7 min in a shaking water bath. After
seven successive cycles of digestion, cells pooled from all
digestions were centrifuged at 335 g for 5 min. Cells were
plated onto 100-mm Falcon tissue culture dishes for 90 min
in preplating medium (68% DMEM, 17% M199 medium,
10% horse serum, 5% FBS and 2.5 lgmL1 amphotericin
B) to attach cardiac fibroblasts. Most of the cardiomy-
ocytes remained floating and were collected afterwards.
Cardiomyocytes were then plated on BD Falcon Primaria
plates or on laminin-coated cover slips in plating medium
containing 68% DMEM, 17% M199 medium, 10% horse
serum, 5% FBS, 2.5 lgmL1 amphotericin B and 1 lM
BrdU (5-bromo-2-deoxyuridine). The following day,
NRCMs were washed twice using PBS and then cultured in
maintenance media (80% DMEM, 20% M199, 1% FBS,
2.5 lgmL1 amphotericin B and 1 lM BrdU) at 37 °C.
Intracellular calcium analysis
The fluorescent calcium indicator Indo-1 AM (Molecular
Probes, Eugene, OR, USA) was used to measure cytosolic
free calcium. NRCMs were plated on laminin-coated glass
coverslips. Cells were loaded with 5 lM Indo-1 AM for
15 min at 37o C in the dark. The cells were then washed
with maintenance media and incubated for further 30 min
at 37 °C to de-esterify the dye completely. The coverslip was
placed in a bath on the stage of an epifluorescence-adapted
inverted Olympus IX70 microscope connected to an Olym-
pus America camera. The myocytes were continuously per-
fused with Tyrode solution (131 mM NaCl, 4 mM KCl,
1 mM CaCl2, 1 mM MgCl2, 10 mM glucose, 10 mM HEPES,
pH 7.4 adjusted with NaOH). The MyoPacer field stimula-
tor (Ionoptix Inc., Westwood, MA, USA) was used for field
stimulation of the cardiomyocytes through two silver wire
electrodes initiating an electrical current at a frequency of 1
Hertz (Hz). Calcium changes occurring during cardiomy-
ocyte contraction were recorded at 37 °C under basal condi-
tions or after stimulation with glycated bovine serum
albumin (AGE-BSA, Calbiochem, EMD Millipore, Biller-
ica, MA, USA) at 0.1–1 mgmL1 for 24 h. For SR calcium
content analysis, calcium transient was measured after
superfusion with 10 mM caffeine in the absence of electrical
field stimulation. The amplitude of the resulting transient
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was used as a measure for the SR calcium content. For ana-
lysing the involvement of NF-jB, cells were treated with
100 nm of NF-jB inhibitor, pyrrolidine dithiocarbamate
(PDTC), for 1 h prior to stimulation with AGE. To examine
the role of NADPH oxidase, we treated NRCM with 1 lM
NADPH oxidase inhibitor, diphenyleneiodonium (DPI), for
1 h prior to stimulation with AGE.
Western blot
Western blots to analyse protein expression were con-
ducted using the standard protocol as described previously
[17,18]. Primary antibodies used were anti-L-type Ca2+
channel (Abcam, Cambridge, UK), anti-ryanodine recep-
tor (Abcam), anti-SERCA2a (Santa Cruz Biotechnology,
Dallas, TX, USA), anti-NCX (Cell Signaling, Danvers,
MA, USA), anti-phospho-PLB (Millipore, Bellerica, MA,
USA), anti-total-PLB (Millipore), anti-PMCA1 (Abcam),
anti-PMCA4 (Abcam), anti-RAGE (Abcam), anti-phos-
pho-p38 (Cell Signaling), anti-total-p38 (Cell Signaling),
anti-iNOS (Abcam), anti-a-tubulin (Calbiochem) and anti-
GAPDH (Santa Cruz). For visualization, we used HRP-
conjugated secondary antibodies, which were obtained
from either Cell Signaling or Dako.
Cell viability and caspase 3/7 analyses
To examine whether AGE treatment induces cell death
and/or apoptosis, we treated NRCMs with 1 mgmL1
AGE for 24 h and performed MTT and caspase 3/7 assays.
For the MTT assay, NRCMs were plated in 24-well plates
at a density of 3 9 105 cells per well. Following 24-h treat-
ment with AGE, 0.45 mgmL1 thiazolyl blue tetrazolium
bromide (Sigma) was added to each well and cells were
incubated for 1 h at 37 °C. Formazan crystals were then
dissolved by adding 100 lL of a solubilization solution
containing 0.1N HCl in isopropanol, and cell viability was
analysed by measuring the absorbance at 570 nm on a
spectrophotometer.
For analysing caspase 3/7 activity, cells were plated at a
density of 3 9 105 and treated with AGE for 24 h. Follow-
ing treatment, cells were lysed for 30 min through the addi-
tion of 100 lL of cell culture lysis reagent (Promega,
Madison, WI, USA). To assess caspase activity, 20 lL of
lysate was mixed with an equal volume of caspase-Glo 3/7
reagent (Promega) and incubated for 1 h at room tempera-
ture. Luminescence was measured using a Lumat lumi-
nometer (Berthold Technologies, Bad Wildbad, Germany).
Immunofluorescence
Immunofluorescence analyses were conducted using the pro-
tocol as described elsewhere [17,18]. To detect NFjB subcel-
lular localization, we used anti-NFjB (p65) (Santa Cruz) and
anti-a-actinin (Sigma) as primary antibodies and detected
using fluorescent-labelled secondary antibodies (Jackson Lab,
West Grove, PA, USA). DAPI was used to stain the nuclei.
To examine S-nitrosylation of RyR and SERCA2a, we used
anti-SERCA2a (Santa Cruz Biotechnology), anti-RYR
(Abcam) and anti-S-nitrosocysteine (Abcam).
NF-jB luciferase assay
We used an adenovirus-containing luciferase reporter dri-
ven by NFjB elements. The generation of the virus has
been described in previous publication [17]. NRCMs were
transduced with the virus 24 h prior to treatment with the
AGE. Luciferase activity was detected 24 h following AGE
treatment using luciferase detection reagent (Promega).
Detection of intracellular reactive oxygen species
Intracellular reactive oxygen species (ROS) level was
assessed using 2,7-dichlorodihydrofluorescein diacetate
(DCF-DA) dye (Molecular Probes). For this procedure,
NRCMs were plated on laminin-coated glass bottom black-
walled 24-well plates at a concentration of 106 cells per
well. Following stimulation with AGE, cells were incubated
with DCF-DA (10 lM) in PBS at 37 °C for 30 min in the
dark. PBS was discarded and replaced by maintenance
media and the cells were immediately used for ROS mea-
surement. Fluorescence was detected using a live cell imag-
ing Leica AS MDW inverted fluorescent microscope where
the cells were kept at 37 °C.
NADPH oxidase assay
For this assay, NRCMs were harvested in PBS. After single
washing step, the cells were resuspended in 1 mM EGTA,
20 mM KH2PO4, 25 mgmL1 leupeptin, 10 mgmL1 apro-
tinin, and 1 mM phenylmethanesulfonyl fluoride. NRCMs
were lysed in this medium by multiple pipetting up and
down on ice. A luminescence assay was used to monitor
NADPH oxidase activity in the cell homogenates. 100 lL
of tissue homogenates was added to 900 lL of 50 mM
phosphate buffer, pH 7.0 (1 mM EGTA, 150 mM sucrose,
500 mM lucigenin, and 100 mM NADPH), where lucigenin
is an electron acceptor and NADPH is the substrate.
NADPH oxidation into NADP by NADPH oxidase
requires an electron transfer. Lucigenin is an electron
acceptor and therefore becomes reduced by the release of
electron. This reaction emits light. Photoemission was mea-
sured every minute for 14 min using a luminometer (Bert-
hold Technologies). The amount of emitted light is used as
an indicator of NADPH oxidase activity. The assay was
repeated on cell homogenates from AGE-treated cells but
with the addition of 25 lM diphenyleneiodonium (DPI)
(NADPH oxidase inhibitor) per reaction mixture. All used
reagents were purchased from Sigma-Aldrich.
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Detection of intracellular nitric oxide
bioavailability
We used nitric oxide (NO)-sensitive fluorescence dye
DAF-FM (4-amino-5-methylamino-20,70-difluorofluorescein)
(Molecular Probes) to measure NO bioavailability. Cul-
tured NRCMs following treatment with AGE were loaded
with 10 lM DAF-FM for 30 min at 37 °C. The medium
containing the dye was discarded and then replaced with
maintenance medium containing 1 mM L-arginine (Sigma-
Aldrich) and incubated for further 45 min at 37 °C for
complete de-esterification of the dye. Fluorescent signal
was detected using a live cell imaging Leica AS MDW
inverted fluorescent microscope where the cells were kept at
37 °C.
Data analysis
Data are expressed as mean  SEM. Student’s t-test or
one-way ANOVA followed by post hoc multiple compar-
ison was used where appropriate. The probability level for
statistical significance was set at P < 0.05.
Results
AGE reduces intracellular calcium transient in
cardiomyocytes
We used primary cardiomyocytes isolated from rat
neonates (NRCM) to study the effects of AGE treat-
ment on intracellular calcium transient. NRCM
expressed AGE receptor (RAGE) as shown by western
blot analysis (Fig. 1A), suggesting that this cell is a
good model to analyse the effect of AGE. Cultured
NRCMs were treated with glycated bovine serum
albumin (AGE-BSA) at a concentration of 1 mgmL1
for 24 h. No change in RAGE expression was
observed following AGE treatment (Fig. 1A). Intracel-
lular calcium was measured using Ca2+ probe Indo-1
and field-stimulated at 1 Hz. AGE treatment signifi-
cantly reduced Ca2+ amplitude by ~50% (Fig. 1B–D).
The rate of Ca2+ decay was also significantly pro-
longed as indicated by analysis of time to 50% base-
line (Fig. 1E). Furthermore, when we treated NRCM
with various doses of AGE ranging from 0.1 to
1 mgmL1, we found that the effect of AGE treat-
ment in reducing Ca2+ amplitude was dose dependent
(Fig. 1F).
AGE reduces SR calcium content
One major determinant of the reduction in Ca2+ tran-
sient amplitude is the level of Ca2+ in the intracellular
Ca2+ storage, that is the sarcoplasmic reticulum (SR)
Ca2+ content. To determine the SR Ca2+ content, we
treated AGE-stimulated and control cells with 10 mM
caffeine in the absence of field stimulation. Data
shown in Fig. 2A,B indicated that the SR Ca2+ con-
tent was significantly reduced in AGE-treated cells by
~32%, which may contribute to the decline in the
Ca2+ transient amplitude described above.
Expression of calcium-handling molecules are
not altered by AGE treatment
Next, we examined whether the change in intracellular
Ca2+ dynamic in AGE-treated NRCM was due to
changes in the expression levels of Ca2+ handling pro-
teins. Protein extracts from NRCM treated with
1 mgmL1 AGE for 24 h and control cells were sub-
jected to western blot analysis to measure expression
of ryanodine receptor (RyR), SERCA2a, L-type Ca2+
channel (LTCC), sodium calcium exchanger (NCX),
isoform 1 and 4 of the plasma membrane calcium
ATPase (PMCA1 and PMCA4) as well as phospho-
rylated and total phospholamban (PLB). Western
blots and subsequent quantification of band density
showed that there was no difference in the expres-
sion levels of Ca2+ handling proteins following
treatment with AGE (Fig. 3A–G). These data sug-
gested that the effect of AGE treatment was mainly
due to alteration of protein function rather than
level of expression.
Induction of reactive oxygen species formation
by AGE
It has been reported that in endothelial and hepatic
stellate cells, RAGE activation by AGE may induce
the formation of reactive oxygen species (ROS) via
activation of NADPH oxidase [19,20]. To investigate
whether ROS level was elevated in NRCM following
AGE exposure, we used a ROS-sensitive dye (DCF-
DA) to measure intracellular ROS. We found a signifi-
cant increase in intracellular ROS level in AGE-treated
NRCM as indicated in Fig. 4A,B.
We then examined whether NADPH oxidase activity
was increased in these cells. NADPH oxidase assay was
performed on fresh cell lysates of AGE-treated and con-
trol NRCM. A significant increase in NADPH oxidase
activity was detected in AGE-treated NRCM compared
to control cells (Fig. 4C). Furthermore, addition of
NADPH oxidase inhibitor diphenyleneiodonium (DPI,
25 lM) inhibited the difference between AGE-treated
and control NRCM (Fig. 4D), strongly supporting the
idea that AGE treatment increased NADPH oxidase
activity.
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NADPH oxidase may be involved in AGE-induced
intracellular calcium changes
To further analyse whether elevated NADPH oxi-
dase was responsible for the changes in intracellular
Ca2+ dynamics, we treated NRCM with 1 lM DPI
for 1 h before adding AGE (1 mgmL1) for a fur-
ther 24 h. We then analysed the Ca2+ transient in
comparison with nontreated NRCM. As described in
Fig. 4E,F, there was no difference in Ca2+ transient
amplitude between these groups of NRCM, suggest-
ing that DPI treatment might suppress the effect of
AGE on NRCM. Taken together, the data above
indicated that NADPH oxidase was involved in
mediating the effects of AGE treatment on car-
diomyocytes.
NRCM viability following AGE treatment
As the ROS level was significantly increased in AGE-
treated NRCM, it was important to examine whether
this affected cell viability and/or apoptosis. Therefore,
we performed an MTT assay and analysed caspase 3/7
activity in NRCM treated with 1 mgmL1 AGE for
24 h. We found that there was no significant difference
in cell viability or apoptosis levels between AGE-trea-
ted and control cells as indicated by MTT and caspase
3/7 assay, respectively (Fig. 4G,H).
p38 kinase and NFjB are activated by AGE
It has previously been reported that RAGE activation
by AGE may induce phosphorylation of members of
Fig. 1. Advanced glycated end products (AGEs) reduce intracellular calcium transient in isolated cardiomyocytes. (A) Representative western
blots showing the expression of AGE receptor (RAGE) and loading control (a-tubulin) in neonatal rat cardiomyocytes (NRCM) with or without
treatment with AGE (1 mg/mL for 24 h). (B) Representative intracellular calcium traces obtained from NRCM showing reduction in calcium
transient amplitude and decay rate following AGE treatment (1 mg/mL for 24 h). Cells were loaded with Indo-1 and field-stimulated at a
frequency of 1 Hz. (C) Average trace of calcium transients from control and AGE-treated cardiomyocytes (1 mg/mL for 24 h). (D)
Quantification of calcium amplitude and (E) time to 50% baseline showed a significant decrease in calcium amplitude (P < 0.001) and
significant prolongation of time to 50% baseline (P < 0.01) (n = 18 cells from three independent NRCM preparations). (F) Dose-dependent
reduction in calcium transient amplitude in NRCMs treated with 0.1–1 mg/mL AGE for 24 h (n = 8–18 cells).
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the mitogen-activated protein kinases (MAPKs) path-
way, in particular the p38 kinase [21]. Activation of
this kinase modulates activation of the NFjB pathway
[22]. To investigate the involvement of these signalling
molecules, we analysed the level of phosphorylated
p38 kinase by western blots and activation of NFjB
pathway following AGE treatment. Analysis of phos-
phorylated/total protein levels revealed that phospho-
rylation of p38 kinase was elevated in NRCM treated
with AGE (Fig. 5A). Furthermore, assessment of
NFjB activity using adenovirus-delivered NFjB luci-
ferase reporter construct showed a marked increase in
NFjB activity following AGE treatment in a dose-
dependent manner (Fig. 5B). This finding was con-
firmed by immunofluorescence analysis, in which we
found enhanced level of NFjB nuclear translocation
in AGE-treated NRCM, indicating activation of this
transcription factor (Fig. 5C).
The AGE-induced Ca2+ transient change is NFjB
dependent
We used a NFjB inhibitor pyrrolidine dithiocarba-
mate (PDTC) to test whether NFjB is required in
mediating the AGE-induced Ca2+ transient change in
NRCM. NRCMs were treated with AGE (1 mgmL1)
in the presence of 100 nM PDTC for 24 h. We
observed that there was no difference in Ca2+ tran-
sient amplitude as well as Ca2+ decay rate between
treated NRCM and control cells, indicating that
PDTC suppressed the effect of AGE treatment in
Ca2+ transient (Fig. 5D–F).
iNOS expression and nitric oxide level are
elevated following AGE treatment
It has been reported that AGE accumulation is also
related to nitric oxide (NO) production in kidney mesan-
gial cells [23], endothelial cells [24] and macrophages
[25]. We therefore sought whether the level of NO
bioavailability was altered in AGE-treated cardiomy-
ocytes. Using NO-sensitive dye DAF-FM, we observed
significantly higher level of NO bioavailability in AGE-
treated cardiomyocytes compared to control (Fig. 6A,B).
Of three different isoforms of NO synthases, the
inducible NO synthase (iNOS) is known to be modu-
lated by p38 kinase and NFjB transcription factor
[23]. We therefore examined iNOS expression by west-
ern blot and found that iNOS expression was signifi-
cantly elevated in AGE-stimulated NRCM (Fig. 6C,
D). These data suggested that iNOS expression might
contribute to the elevation of NO bioavailability fol-
lowing AGE treatment.
S-Nitrosylation of calcium-handling proteins in
AGE-treated NRCM
Increased production of both NO and superoxide may
induce the formation of peroxynitrite that can cause
nitrosylation of thiol groups of particular proteins and
hence impair their functions [26,27]. As an initial step to
test whether the increased ROS/NO generation shown
above induced S-nitrosylation of major Ca2+ channels
in AGE-treated cardiomyocytes, we analysed S-nitrosyla-
tion of ryanodine receptor and SERCA2a in AGE-treated
Fig. 2. Advanced glycation end products reduce sarcoplasmic reticulum (SR) calcium content. (A) Example of calcium traces showing the
response to 10 mM caffeine in control and AGE-treated NRCM (1 mg/mL, 24 h). Field stimulation was stopped prior to caffeine induction.
(B) Quantification of fluorescent signal suggested a significant decrease in SR calcium content (P < 0.01) in AGE-treated cells compared to
control (n = 9–11 cells from three independent preparations).
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cells. For this purpose, we performed immunofluorescence
analysis followed by detection using confocal microscopy.
As shown in Fig. 7A,B, we found substantial colocaliza-
tion between S-nitrosylated protein and the ryanodine
receptor, and to a lesser extent with the SERCA2a.
Together, these data suggest that S-nitrosylation of cal-
cium-handling proteins may be a contributing factor in
causing the reduced SR content and amplitude of calcium
transient after AGE treatment.
Discussion
Advanced glycation end products (AGEs) have been
known to play important roles in inducing diabetes
Fig. 3. Advanced glycation end product treatment does not alter expression of major calcium channels. Representative western blots of (A)
L-type calcium channel (LTCC), (B) ryanodine receptor (RyR), (C) sodium/calcium exchanger (NCX), (D) sarcoplasmic reticulum ATPase 2a
(SERCA2a), (E) plasma membrane calcium ATPase 1 (PMCA1), (F) PMCA4 and (G) phosphorylated and total phospholamban (p/t-PLB)
accompanied with loading controls (GAPDH/a-tubulin). Quantification of band densities as described by the bar graphs suggested that there
was no significant change in protein expressions following AGE treatment (1 mg/mL, 24 h; n = 6–8).
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complications in many organs including heart. In this
study, we reveal signalling pathways that may be
involved in mediating AGE effects in cardiomyocytes,
in particular in the regulation of intracellular Ca2+
homeostasis. As intracellular Ca2+ is key in
determining contractile function, our finding may
explain the molecular events leading to the develop-
ment of cardiomyopathy in patients with diabetes.
We used neonatal rat cardiomyocytes (NRCM) as a
model in this study as these cells express the receptor
Fig. 4. Advanced glycation end products induce intracellular reactive oxygen species (ROS) level and NADPH oxidase activity. (A) Images of
control and AGE-treated NRCMS stained with ROS-sensitive dye DCF-DA. (B) Quantification of fluorescence intensity indicated a
significantly higher ROS level in NRCM treated with AGE (1 mg/mL, 24 h) (P < 0.001, n = 38–48 cells). (C) NADPH oxidase activity
measurement in AGE-treated and control NRCMs showed that AGE-treated NRCM exhibited a significant increase (P < 0.01) in NADPH
oxidase activity compared to the control cells (n = 7–9). (D) Addition of NADPH oxidase inhibitor diphenyleneiodonium (DPI, 25 lM) inhibited
the difference between control and AGE-treated NRCM (n = 5). (E) Examples of calcium traces from control and AGE-treated NRCMs
(1 mg/mL, 24 h) in the presence of 1 lM DPI. (F) Quantification of calcium amplitude showed no difference between control and
AGE + DPI-treated NRCM, indicating that DPI treatment suppressed the effect of AGE. (G) NRCM viability following treatment with AGE
(1 mg/mL, 24 h) was assessed using MTT assay. There was no difference in the MTT colorimetric signal intensity between control and
AGE-treated cells (n = 12 in each group), suggesting that there was no difference in cell viability between these groups. (H) Consistently,
analysis of caspase 3/7 activity showed that there is no difference in apoptosis level between AGE-treated and control cells (n = 12 in each
group).
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of AGE (RAGE). We found that AGE treatment
markedly reduced Ca2+ transient amplitude, Ca2+
decay rate and the SR Ca2+ content. Our data are
consistent with previous observation showing that
AGE treatment reduces SR Ca2+ content and Ca2+
amplitude in cardiomyocytes [28]. However, in
addition to that finding, we also showed in this study
that the expression levels of major Ca2+ regulators
were not altered, suggesting that AGE modified the
function rather than the expression of Ca2+ channels.
We also found signalling events induced by AGE
treatment in NRCM, which might be related to each
Fig. 5. Treatment with AGE induces p38 MAPK and NFjB activation in NRCM. (A) Western blots of phosphorylated and total p38 kinase
and quantification of band density showed a significant increase in phosphorylated/total p38 level in AGE-treated NRCM (P < 0.05, n = 6).
(B) Assessment of NFjB activity using NFjB luciferase reporter construct indicated a dose-dependent increase in NFjB activity following
AGE treatment (0.4–1 mg/mL, 24 h, *P < 0.05, ***P < 0.001, n = 9 in each groups). (C) Immunofluorescent staining of AGE-treated (1 mg/
mL, 24 h) and control NRCM. Cells were stained with anti-NFjB antibody (green), phalloidin (red) and DAPI (blue). AGE treatment induced
NFjB nuclear translocation. (D) Representative calcium traces of control and AGE-treated NRCMs (1 mg/mL, 24 h) in the presence of NFjB
inhibitor pyrrolidine dithiocarbamate (PDTC, 100 nM). (E) Quantification of calcium amplitude and (F) time to 50% baseline showed no
difference between control and AGE + PDTC-treated NRCM, indicating that NFjB inhibition suppressed the effect of AGE (n = 14 cells in
each group).
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other and might contribute to the AGE-induced alter-
ation of Ca2+ homeostasis: (a) elevation of reactive
oxygen species (ROS), (b) induction of NADPH
oxidase activity, (c) activation of p38 kinase and
NFjB and (d) induction of iNOS expression and NO
level.
Fig. 6. Nitric oxide (NO) bioavailability and iNOS expression are increased following AGE treatment. (A) Representative images of control
and AGE-treated NRCM stained with NO-sensitive dye DAF-FM. (B) Quantification of DAF-FM fluorescent signal revealed a significantly
higher NO bioavailability in AGE-treated NRCM compared to control (P < 0.05, n = 94–106 cells). (C) Representative western blots and (D)
quantification of band density showing expression of iNOS in control and AGE-treated NRCM (P < 0.01, n = 7 in each group).
Fig. 7. S-Nitrosylation of ryanodine
receptor and SERCA2a in AGE-treated
NRCM. (A) Representative
immunofluorescence detection of S-
nitrosylated protein (green), ryanodine
receptor (red) and the merged images
showing increased S-nitrosylation in AGE-
treated cells and the colocalization of S-
nitrosylation signal (arrows) with ryanodine
receptor. (B) Similar analysis was also
performed to detect S-nitrosylation of
SERCA2a. S-Nitrosylation (green) was
increased in AGE-treated cells and
colocalization with SERCA2a (red) was
also detected although at a lower level
than that observed with the ryanodine
receptor. Nuclei were stained blue with
DAPI.
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Oxidative stress is a key factor in the pathophysiol-
ogy of diabetic complications [29]. RAGE activation
following binding with AGE has been shown to medi-
ate oxidative stress in a number of tissues including
vascular [30,31], renal [32,33] and neuronal tissues [34].
Our data showing that AGE-treated cardiomyocytes
contain higher level of ROS are in line with previous
observation [28,35]. It is also consistent with the idea
that RAGE activation induces ROS production [36].
However, in this study, we also demonstrated the possi-
ble source of ROS elevation. We found that NADPH
oxidase activity was markedly increased in AGE-treated
cardiomyocytes. Indeed, activation of NADPH oxidase
by AGE has been observed in different cell types such
as hepatic cells [19] and renal mesangial cells [37].
Importantly, our data also showed that the induced
NADPH oxidase activity might be responsible for
reducing the Ca2+ transient in AGE-treated cells as we
found that NADPH oxidase inhibition using DPI nor-
malized Ca2+ transient amplitude to basal levels.
To further examine the downstream signalling path-
way, we analysed activation of p38 kinase as this
kinase is part of the major stress pathway (the MAPK
pathway) and has been associated with the NADPH
oxidase-derived ROS [38]. Our findings showed a sig-
nificant increase in p38 phosphorylation that indicated
activation of this kinase. Indeed, AGE has been asso-
ciated with activation of MAP kinase pathway in car-
diomyocytes previously [35]. This is also consistent
with published observations in different cell types,
which showed activation of p38 kinase by NADPH
oxidase and ROS [39,40]. However, in this study, we
also show the signalling pathway downstream of p38
that might be activated by AGE treatment. We
observe activation and nuclear translocation of the
transcription factor NFjB. Using luciferase reporter
system and then confirmed by immunofluorescent stain-
ing, we detected higher NFjB activity and more nuclear
NFjB in the AGE-treated cardiomyocytes. NFjB acti-
vation might be associated with p38 kinase as it has
been known that p38 kinase controls NFjB activation
and nuclear translocation in various cell types
[22,41,42]. Our present findings confirmed that this reg-
ulatory process also occurs in cardiomyocytes in the set-
ting of AGE exposure. Equally important, we also
confirmed that the NFjB signal contributed to the
reduction in Ca2+ dynamic, as indicated by the inhibi-
tor experiments, adding to the functional importance of
the pathway in the context of high AGE exposure.
We then investigated the downstream effector of
NFjB activation by AGE in cardiomyocytes. We
focused on NO signalling, in particular those regulated
by inducible NOS (iNOS). This is because (a) RAGE
activation upregulates NO production by iNOS [43];
(b) iNOS is known as a gene target of NFjB tran-
scription factor [23]; (c) NO is a major regulator of
Ca2+ transient in cardiac myocytes [44–46]. Our data
suggested that in cardiac myocytes AGE treatment
might induce iNOS upregulation, which in turn
increased intracellular NO level. Although at physio-
logical levels NO may be beneficial, it is believed that
supraphysiological concentrations of NO may inhibit
the activity of specific Ca2+ channel such as ryanodine
receptor [47]. Furthermore, simultaneous enhanced
intracellular generation of both NO and superoxide
above the physiological levels may cause excessive
nitrosylation of nonspecific cysteine residues, a process
known as poly-S-nitrosylation [26]. S-Nitrosylation has
been shown to modulate the function of major calcium
regulator proteins such as SERCA, ryanodine receptor
and L-type Ca2+ channel (reviewed in [27]). Physiolog-
ical level of S-nitrosylation is needed for optimum
function of the Ca2+ channel; for example, normal
nitrosylation level will activate ryanodine receptor
opening [48] but too much nitrosylation will inhibit its
function [47]. Our initial assessment of S-nitrosyla-
tion levels of ryanodine receptor and SERCA2a sup-
ports this idea as we observed increased levels of S-
nitrosylated proteins which were colocalized with
ryanodine receptor and SERCA2a in NRCM treated
with AGE.
Taken together, our data support the presence of a
pathway in cardiomyocytes that is regulated by AGE
treatment and may be important in modulating the
Fig. 8. Schematic diagram showing the signalling pathway
activated by AGE treatment in cardiomyocytes. RAGE activation by
AGE leads to the elevation of ROS and NO via activation of
NADPH oxidase and the p38 kinase/NFjB pathway. Elevated ROS
and NO may interfere with the functions of calcium-handling
proteins, likely in part due to S-nitrosylation.
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intracellular Ca2+ transient. AGE-induced activation of
RAGE may stimulate NADPH oxidase and hence
production of ROS. This may activate p38 kinase, in
turn activating NFjB and promoting its nuclear
translocation. This may then induce iNOS expression
eventually resulting in increased intracellular NO levels,
which together with the increased ROS may then
alter Ca2+ handling through S-nitrosylation of key
proteins (Fig. 8).
In summary, our study has identified signalling
molecules that may be involved in mediating the
effects of exposure of advanced glycated end products
(AGEs) in cardiomyocytes. The data will add to the
growing body of evidence on the crucial roles of AGE
in mediating diabetes complications. It also underlines
that targeting component(s) of this signalling axis may
be useful to prevent the development of AGE-induced
cardiomyocyte dysfunction.
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